I. Bodrogi
Impact in
- Pulmonary and Respiratory Medicine top 0.1%
- Renal cell carcinoma treatment
- Prostate Cancer Treatment and Research
- Cancer Research top 0.5%
- Cancer Genomics and Diagnostics
Papers in
- Surgery 33
- Testicular diseases and treatments 27
-
- Renal cell carcinoma treatment 8
- Prostate Cancer Treatment and Research 7
- Sarcoma Diagnosis and Treatment 5
- Co-authors
- Oliver Sartor (4 shared papers)Stéphane Oudard (6 shared papers)Mustafa Özgüroğlu (3 shared papers)Liji Shen (3 shared papers)Gwénaëlle Gravis (3 shared papers)Ivo Kocák (3 shared papers)Johann S. de Bono (4 shared papers)Steinbjørn Hansen (3 shared papers)
- Journals
- Journal of Clinical Oncology (12 papers)Oncology (6 papers)Annals of Oncology (3 papers)Journal of Cancer Research and Clinical Oncology (2 papers)The Lancet (2 papers)
- Partner nations
- HungaryFranceUnited States
In The Last Decade
I. Bodrogi
70 papers receiving 10.4k citations
I. Bodrogi's Hit Papers
Peers
Comparison fields: 5 of 106
- Pulmonary and Respiratory Medicine 5.7k
- Cancer Research 2.2k
- Oncology 2.6k
- Surgery 2.2k
- Molecular Biology 3.3k
Countries citing papers authored by I. Bodrogi
This map shows the geographic impact of I. Bodrogi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by I. Bodrogi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites I. Bodrogi more than expected).
Fields of papers citing papers by I. Bodrogi
This network shows the impact of papers produced by I. Bodrogi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by I. Bodrogi. The network helps show where I. Bodrogi may publish in the future.
Co-authors
The 25 scholars most cited alongside I. Bodrogi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 81 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma Hit paper breakdown → | 2007 | 2943 |
| 2 | Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Hit paper breakdown → | 2010 | 2482 |
| 3 | Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial Hit paper breakdown → | 2007 | 1785 |
| 4 | Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study Hit paper breakdown → | 2000 | 1745 |
| 5 | 2009 | 270 | |
| 6 | 2007 | 245 | |
| 7 | 1998 | 211 | |
| 8 | 2004 | 124 | |
| 9 | 1998 | 123 | |
| 10 | 1998 | 105 | |
| 11 | 2008 | 84 | |
| 12 | 2011 | 69 | |
| 13 | 2009 | 40 | |
| 14 | 2004 | 40 | |
| 15 | 2006 | 37 | |
| 16 | 2003 | 35 | |
| 17 | Influence of hMLH1 methylation, mismatch repair deficiency and microsatellite instability on chemoresistance of testicular germ-cell tumors. | 2006 | 31 |
| 18 | 2004 | 25 | |
| 19 | 2004 | 23 | |
| 20 | Drug resistance and sensitivity of germ cell testicular tumors: evaluation of clinical relevance of MDR1/Pgp, p53, and metallothionein (MT) proteins. | 1998 | 22 |
About I. Bodrogi
I. Bodrogi is a scholar working on Surgery, Pulmonary and Respiratory Medicine, Molecular Biology, Oncology and Cancer Research, having authored 81 papers that have together received 10.7k indexed citations. Recurring topics across this work include Testicular diseases and treatments (27 papers), Renal cell carcinoma treatment (8 papers), Prostate Cancer Treatment and Research (7 papers), Cancer Treatment and Pharmacology (6 papers), Sarcoma Diagnosis and Treatment (5 papers), Cancer, Lipids, and Metabolism (5 papers), Cancer therapeutics and mechanisms (5 papers) and Radiopharmaceutical Chemistry and Applications (5 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (5.7k citations), Cancer Research (2.2k citations), Oncology (2.6k citations), Surgery (2.2k citations) and Molecular Biology (3.3k citations). I. Bodrogi has collaborated with scholars based in Hungary, France and United States. Frequent co-authors include Oliver Sartor, Stéphane Oudard, Mustafa Özgüroğlu, Liji Shen, Gwénaëlle Gravis, Ivo Kocák, Johann S. de Bono, Steinbjørn Hansen, Mary J. MacKenzie and Martin Roessner. Their work appears in journals such as Journal of Clinical Oncology, Oncology, Annals of Oncology, Journal of Cancer Research and Clinical Oncology and The Lancet.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.